Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

168 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Risk-adapted letermovir prophylaxis based on a scoring system predicting a higher burden of cytomegalovirus exposure after allogeneic hematopoietic cell transplantation.
Kawamura S, Fujiwara SI, Kimura SI, Takeshita J, Nakasone H, Yoshimura K, Nakata Y, Ishikawa T, Matsuoka A, Meno T, Nakamura Y, Kawamura M, Yoshino N, Misaki Y, Gomyo A, Kusuda M, Murahashi R, Umino K, Minakata D, Ashizawa M, Yamamoto C, Hatano K, Sato K, Ohmine K, Kako S, Kanda Y. Kawamura S, et al. Among authors: misaki y. Transplant Cell Ther. 2025 Jan 17:S2666-6367(25)00911-X. doi: 10.1016/j.jtct.2025.01.883. Online ahead of print. Transplant Cell Ther. 2025. PMID: 39828058
Clinical impact of a change in antibiotics or the addition of glycopeptide antibiotics for persistent febrile neutropenia after autologous stem cell transplantation.
Yoshino N, Kimura SI, Kawamura K, Nakata Y, Matsuoka A, Ishikawa T, Meno T, Nakamura Y, Kawamura M, Kawamura S, Takeshita J, Misaki Y, Yoshimura K, Gomyo A, Okada Y, Tamaki M, Kusuda M, Kameda K, Akahoshi Y, Sato M, Tanihara A, Nakasone H, Kako S, Kanda Y. Yoshino N, et al. Among authors: misaki y. J Infect Chemother. 2025 Jan;31(1):102455. doi: 10.1016/j.jiac.2024.06.018. Epub 2024 Jun 24. J Infect Chemother. 2025. PMID: 38925426
Decision analysis for transplant candidates with primary myelofibrosis in the ruxolitinib era.
Okada Y, Nakasone H, Kawamura S, Takano K, Yoshimura K, Tamaki M, Matsuoka A, Ishikawa T, Meno T, Nakamura Y, Kawamura M, Takeshita J, Yoshino N, Misaki Y, Kusuda M, Tanihara A, Kimura SI, Kako S, Kanda Y. Okada Y, et al. Among authors: misaki y. Haematologica. 2024 Nov 1;109(11):3593-3601. doi: 10.3324/haematol.2024.285256. Haematologica. 2024. PMID: 38899343 Free PMC article.
Phase 2 trial of induction with dasatinib and consolidation with hyper-CVAD plus dasatinib followed by allografting for Ph-positive acute lymphoblastic leukemia in adults.
Oh I, Hatano K, Ikeda T, Toda Y, Minakata D, Kawaguchi S, Morita K, Yamamoto C, Ashizawa M, Sato K, Kameda K, Gomyo A, Misaki Y, Kawamura S, Kimura S, Kobayashi H, Sato H, Nakasone H, Ohmine K, Fujiwara S, Kako S, Kanda Y. Oh I, et al. Among authors: misaki y. Leuk Res. 2024 Feb;137:107438. doi: 10.1016/j.leukres.2024.107438. Epub 2024 Jan 17. Leuk Res. 2024. PMID: 38278044 Clinical Trial. No abstract available.
Gilteritinib Monotherapy as a Transplant Bridging Option for a Patient with FLT3-Mutated Acute Promyelocytic Leukemia Who Developed a Second Relapse after All-Trans Retinoic Acid + Chemotherapy, Arsenic Trioxide, and High-Dose Cytarabine Therapy.
Kobayashi H, Tsutsumi H, Misaki Y, Maekawa T, Inoshita N, Kawamura M, Maseki N. Kobayashi H, et al. Among authors: misaki y. Case Rep Hematol. 2023 Dec 13;2023:8568587. doi: 10.1155/2023/8568587. eCollection 2023. Case Rep Hematol. 2023. PMID: 38124780 Free PMC article.
168 results